Compare Cassava Sciences Inc (FLNA) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Mattel Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Mattel Inc trades at $14.63 (market cap $4.03B). The key difference: Mattel Inc is far larger — about 75.8× Cassava Sciences Inc's market cap, and Mattel Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | MAT | |
|---|---|---|
Market Cap | $53.14M | $4.03B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $22.16 |
52-Week Low | $1.09 | $13.05 |
Enterprise Value | -$33.43M | $5.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Mattel (MAT) trades at $13.67, down 1.23% on the day, with a bearish technical signal from moving averages. The company maintains solid fundamentals with a P/E of 8.88 and net income margin of 9.27%, though recent quarters showed mixed earnings results. Positive sentiment is driven by new product launches like Hot Wheels collaborations and Barbie brand expansions, while analyst consensus remains bullish with a $14.60 price target.
The outlook for Mattel is cautiously optimistic, supported by strong brand portfolio and valuation appeal, but tempered by recent earnings misses and a negative net cash flow trend. Key risks include execution on new initiatives and competitive pressures in the toy industry. Upside potential exists if upcoming Q2 2026 earnings beat expectations and brand momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
